INNOSTAR: The holding subsidiary Shenzhen INNOSTAR will undergo business adjustments

INNOSTAR announced that in order to further optimize capacity allocation, reduce management costs, and improve management efficiency and control capabilities, its holding subsidiary Shenzhen INNOSTAR Biomedical Safety Evaluation Research Institute Co., Ltd. will undergo business adjustments and will no longer undertake new businesses except for existing ones. Shenzhen INNOSTAR was established in November 2021, with a registered capital of 20 million yuan. As of 2024, the total assets were 115 million yuan, net assets were -64.8761 million yuan, operating income was 65.7117 million yuan, and net profit was -21.5035 million yuan. As of March 31, 2025, total assets were 105 million yuan, net assets were -71.6134 million yuan, operating income was 14.9232 million yuan, and net profit was -6.7373 million yuan